eteplirsen - Profile

What are the generic sources for eteplirsen and what is the scope of freedom to operate?

Eteplirsen is the generic ingredient in one branded drug marketed by Sarepta Theraps Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Eteplirsen has one hundred and twenty-eight patent family members in twenty-three countries.

Summary for eteplirsen

International Patents:	128
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for eteplirsen

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for eteplirsen

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for eteplirsen

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes			Y
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016		RX	Yes	Yes

Expired US Patents for eteplirsen

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016

EU/EMA Drug Approvals for eteplirsen

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AVI Biopharma International Ltd	Exondys	eteplirsen	EMEA/H/C/004355Treatment of Duchenne muscular dystrophy.	Refused	no	no	yes		2018-12-06

International Patents for eteplirsen

Country	Patent Number	Title	Estimated Expiration
Slovenia	2607484
Australia	2008317566	Means and methods for counteracting muscle disorders
Australia	2009310557	Methods and means for efficient skipping of exon 45 in Duchenne Muscular Dystrophy pre-mRNA
Spain	2562658
Australia	2009310558	Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50- 53.
Brazil	112015022998	composições melhoradas para o tratamento de distrofia muscular

Eteplirsen: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Eteplirsen, marketed as Exondys 51, is a dystrophin splice-modulating antisense oligonucleotide developed by Sarepta Therapeutics for Duchenne Muscular Dystrophy (DMD). Approved by the U.S. FDA in September 2016 under accelerated approval conditions, its commercial prospects depend on regulatory, competitive, and reimbursement landscapes. This report evaluates eteplirsen's investment potential by analyzing market size, competitive dynamics, regulatory trends, and financial trajectory from 2023 onward.

---

Overview of Eteplirsen

Parameter	Details
Mechanism of Action	Exon 51 skipping via antisense oligonucleotide
Indication	Duchenne Muscular Dystrophy (DMD), subset of patients with mutations amenable to exon 51 skipping
Regulatory Status	Approved in the U.S. (2016); conditional approvals elsewhere; ongoing post-marketing studies
Pricing and Revenue	Approved price approximately $300,000/year per patient in the U.S.
Market Authorizations	US, Europe, Japan (pending or limited), and other territories

Market Dynamics for DMD Agents

DMD Market Overview

Aspect	Details
Prevalence (US)	Estimated 15,000–25,000 patients; approximately 1 in 3,600–6,000 male births
Eligible Population for Exon 51	~13,000-15,000 globally; US estimate 4,000–5,000 patients
Growth Rate	CAGR of approximately 3% in DMD population (due to improved diagnostics and awareness)
Treatment Landscape	Limited to exon skipping therapies: eteplirsen, golodirsen, viltolersen, and emerging gene therapies

Key Competitive Agents

Drug	Developer	Mechanism	Regulatory Status	Pricing (USD/year)
Eteplirsen	Sarepta Therapeutics	Exon 51 skipping	Approved (2016, US); others varying	~$300,000
Golodirsen	Sarepta Therapeutics	Exon 53 skipping	FDA approved (2020)	~$300,000
Viltolersen	Restore Bio (joint venture with Genethon)	Exon 53 skipping	FDA-approved (2020); Japan	~$300,000
Gene therapies	Sarepta (SRP-9001), others	Gene replacement therapies	Under review or in trials	$900,000–$2 million (projected)

Regulatory and Reimbursement Landscape

Policy/Trend	Impact on Market & Investment
Accelerated Approval Pathway	Facilitate rapid market entry but requires confirmatory trials for continued approval
Reimbursement Challenges	US payers scrutinize high-cost therapies; outcomes-based agreements are emerging
EMA & Other Regulators	Authorizations often limited; reimbursement subject to individual country policies
Pricing Pressures	Cost containment initiatives threaten high-price drugs like eteplirsen

---

Financial Trajectory and Revenue Forecasts

Current Revenue Profile

Year	Estimated US Patients	Estimated Global Patients	Revenue (USD mill.)	Notes
2022	~1700	~2,000	~$510 million	US sales dominate, growth from new patients & uptake
2023	~2000	~2,400	~$600 million	Increased diagnosis, expanded access
2024+	Growth moderates	Slight increase	~$700–900 million	Market saturation, price pressure, and new competing therapies

Long-term Revenue Drivers

• Market Penetration: Broadening diagnosis and approval expansion.
• Pricing Strategy: Maintaining high per-patient prices amid payer negotiations.
• Patient Access Programs: Use of managed entry schemes to mitigate reimbursement hurdles.
• Regulatory Outcomes: Additional approvals (e.g., in Europe) can expand addressable population.
• Pipeline Development: Next-generation antisense and gene therapies could impact revenues.

Sensitivity Analysis

Variable	Impact on Revenue	Assumption Details
Pricing reduction	Significant	10-15% cost reductions via negotiations
Patient enrollment growth	Moderate	3-5% CAGR in eligible population
Regulatory delays or denials	Negative	Slower approval or coverage restrictions
Emergence of durable gene therapies	Major	Potential to supplant eteplirsen as first-line treatment

---

Comparison with Competing and Emerging Therapies

Aspect	Eteplirsen	Gene therapies	Small molecules/Other exon skipping therapies
Mechanism	Exon 51 skipping	Gene addition/editing	Exon skipping, small molecules
Regulatory Status	Approved, post-market phase	Under review or in early trials	Predominantly late-stage or preclinical
Durability of Benefit	Uncertain; limited long-term data	Potentially curative	Symptomatic, requiring chronic administration
Pricing & Reimbursement	~$300,000/year	Up to $2 million (estimated)	Varies; generally lower than eteplirsen

Regulatory and Patent Considerations

Factor	Details
Patent Expiry	Composition patent expiring circa 2028; process patents beyond that.
Regulatory Risks	Continued post-marketing requirements; real-world evidence collection
Off-label Use & Reimbursement	Potential restrictions impacting revenue streams

---

Deep Dive: Investment Outlook and Risks

Opportunities

• Growing Diagnosed Population: Increased awareness and newborn screening expand treatable cohorts.
• Approval Expansion: European and Asian markets provide revenue upside.
• Pipeline Synergies: Adjunct or successor therapies to extend market leadership.
• Price Negotiations: Value-based arrangements with payers to sustain high prices.

Risks

• Regulatory Delays/Denials: Post-approval studies and confirmatory trials could jeopardize market access.
• Market Penetration: Slow adoption due to reimbursement barriers or clinical skepticism.
• Emerging Therapies: Gene editing (e.g., CRISPR) and more durable treatments threaten long-term dominance.
• Pricing Pressures: Payer resistance threatens profit margins.

---

Conclusion and Key Takeaways

Element	Insight
Market size & growth	US DMD patients for exon 51 skipping therapies total ~4,000–5,000; global potential expands
Investment potential	Moderate-to-high; contingent on regulatory, reimbursement, and pipeline developments
Competitive landscape	Limited approved exon skipping drugs; gene therapies emerging as formidable rivals
Revenue trajectory	Expected to plateau or grow modestly; high ongoing costs and payer scrutiny are key challenges
Regulatory environment	Critical to monitor; additional approvals can diversify revenue sources

---

Frequently Asked Questions

1. What is the current primary revenue driver for eteplirsen?
   Eteplirsen's revenue primarily derives from US sales, with an estimated $300,000 annual price per patient and an expanding patient population due to increased awareness and diagnosis.

2. How does eteplirsen compare to emerging gene therapies for DMD?
   While eteplirsen offers a non-invasive, exon-specific approach with proven, albeit limited, long-term benefit, gene therapies aim for potentially curative outcomes but face regulatory, safety, and manufacturing hurdles. Long-term durability and costs remain under evaluation.

3. What are the main regulatory challenges for eteplirsen?
   Post-approval confirmatory trials are mandated to verify clinical benefit. Regulatory agencies may impose restrictions or withdraw approval if data does not meet endpoints, especially as novel therapies enter the market.

4. How might reimbursement policies affect eteplirsen's future revenue?
   Payers are increasingly scrutinizing high-cost therapies, favoring value-based arrangements. Reimbursement success depends on demonstrating tangible clinical benefit and establishing cost-effectiveness.

5. What is the outlook for new markets and indications?
   Expanding approvals in Europe, the Middle East, and Asia could increase revenue streams. Developing therapies for other exon skip targets or combination modalities remains a future avenue.

---

References

1. US Food and Drug Administration. FDA Approves Sarepta Therapeutics' Exondys 51 for Duchenne Muscular Dystrophy. 2016.
2. Sarepta Therapeutics. Annual Reports (2022–2023).
3. EvaluatePharma. Oncology and Rare Disease Pipeline Analysis, 2022.
4. Globocan. Estimated Prevalence of Duchenne Muscular Dystrophy, 2022.
5. FDA. Post-Marketing Requirements for Eteplirsen, 2016-2023.

---

Key Takeaways

• Eteplirsen remains a high-cost, niche therapy within a limited but expanding market.
• The outlook hinges on regulatory clarity, reimbursement negotiations, and pipeline breakthroughs.
• Competition from gene therapies could significantly alter the market landscape within the next 5–10 years.
• Strategic investment should focus on regulatory milestones, payer engagement, and pipeline advancements to manage risks and capitalize on growth opportunities.